X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the termination agreement, Daewoong regains all rights to the commercialization and clinical development of Fexuclue (fexuprazan), a novel potassium-competitive acid blocker for the treatment of erosive esophagitis, in the U.S. and Canada.
Lead Product(s): Fexuprazan
Therapeutic Area: Gastroenterology Product Name: Fexuclue
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Daewoong Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination June 05, 2023
Details:
Proceeds from the financing will be used to advance the company’s pipeline of GI therapies, DWP14012, for serious conditions that impact millions of people yet are not effectively treated.
Lead Product(s): Fexuprazan
Therapeutic Area: Gastroenterology Product Name: DWP14012
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Vivo Capital
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 26, 2021
Details:
Daewoong Pharmaceutical will take a significant equity stake in Neurogastrx, ramping to 13.5% ownership upon an initial public offering (IPO). Neurogastrx has the exclusive right to develop and commercialize fexuprazan in the U.S. and Canada.
Lead Product(s): Fexuprazan
Therapeutic Area: Gastroenterology Product Name: DWP14012
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Daewoong Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
